Aurora Cannabis Q1 revenue up 17%, adjusted EBITDA rises 209%

Aurora Cannabis

06/08/2025 12:38

Overview

Aurora Cannabis fiscal Q1 2026 rev rises 17%, driven by medical cannabis growth

Adjusted EBITDA for fiscal Q1 grows 209%, reflecting strong operational performance

Co maintains strong balance sheet with $186 mln cash and debt-free cannabis business

Outlook

Aurora expects Q2 2026 net revenue to grow year-over-year

Company anticipates 8%-12% growth in Global Medical Cannabis segment

Aurora sees adjusted gross margins rising by 250-475 basis points

Company expects significant cash outflows to impact Q2 2026 free cash flow

Result Drivers

MEDICAL CANNABIS - 37% increase in global medical cannabis revenue driven by higher sales in Australia, Germany, Poland, and the UK

INTERNATIONAL GROWTH - 85% growth in international medical cannabis revenue, now accounting for 57% of global medical cannabis net revenue

PLANT PROPAGATION - 4% revenue increase due to organic growth and expanded product offerings, despite inventory write-offs

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
C$64.80 mln
Q1 Adjusted EBITDA
C$10.80 mln
Q1 Adjusted Gross Margin
52.0%
Q1 Adjusted Gross Profit
C$49 mln
Q1 Net Income from Cont Ops
-C$19.40 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The stock recently traded at 11 times the next 12-month earnings vs. a P/E of 19 three months ago

Press Release: ID:nCNWvWTKZa

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)